1

BACKGROUND: Pathogen reduction technology (PRT)
enhances blood component safety, but its implementation is hampered by loss of blood quality and cost.
STUDY DESIGN AND METHODS:
A retrospective study was conducted to investigate the efficacy, safety, and cost of 9673 riboflavin and ultraviolet light-treated platelet (PLT) transfusions given to 1211 patients during a 3-year period. The results were compared with the efficacy, safety, and cost of 6424 nontreated PLT transfusions administered to 1500 patients during a 3-year comparison period before PRT implementation.
RESULTS:
Despite a similar PLT transfusion dose per unit for both periods (pre-PRT period 3.26 vs. PRT period 3.19) , the mean number of PLT concentrates per patient (4.2 vs. 7.8; p = 0.006) and the total dose of PLTs received by patients were higher in the PRT period (13.6 vs. 24.8; p = 0.0002). Hematology and medical and surgical patient categories had the highest PLT use per patient. However, febrile (2.5% vs. 1.2%; p = 0.02) and allergic (0.16% vs. 0.08%; p = 0.01) reactions were lower during the PRT period. The blood center saved €284,805.58 due to a reduction of outdated PLTs from 16.8% to 0.72% after PRT implementation.
CONCLUSIONS:
Although PRT can improve PLT safety, it can increase the amount of PLTs required for transfusion in some patient categories. The cost of PRT can be partially offset by the savings associated with a lower rate of PLT outdates. This cost reduction can be a key factor in settings where inventory management is challenged by a high percentage of wasted PLTs due to outdating. P athogen reduction technology (PRT) for blood components can provide significant benefits: 1) enhancing blood safety through the inactivation of viruses, bacteria, and parasites; 2) protecting the blood supply from emerging infectious agents for which laboratory tests might still be unavailable; 1 3) replacing gamma irradiation by inactivating white blood cells (WBCs) not removed by leukoreduction and thereby eliminating the risk of transfusion-transmitted graft-versus-host disease; 2 4) preventing alloimmunization and avoiding platelet (PLT) refractoriness; 3,4 5) reducing the frequency of reactions related to PLT transfusions; 5, 6 and 6) in some settings improving blood supply logistics by increasing the PLT storage time. 7 Thus, PRT that inactivates a broad range of pathogens provides an opportunity to substantially improve transfusion safety, not only by reducing bacterial contamination and sepsis but especially by preventing transfusiontransmissible emerging infectious agents such as the Zika virus. 8 In the Balearic Islands, an archipelago located in the Mediterranean Sea, the Zika virus is not currently a challenge. However, Leishmania infantum and Trypanosoma cruzi are two well-defined emerging pathogens that represent a potential blood safety threat. In the Balearic Islands, as in other areas in southern Europe, 9, 10 there is a 15 Our group has also shown that PLT concentrates collected by apheresis from seropositive T. cruzi blood donors from Latin America presented a higher parasitic load compared to plasma and whole blood (WB). 16 We found that the highest T. cruzi concentration in experimentally infected WB units was in the buffy coat fraction, which would explain the high risk of Chagas disease transmission associated with PLT transfusions described in the literature. 17 The prevention of Chagas disease transfusion transmission was most effective when the PRT was applied to PLTs obtained either from apheresis or buffy coats as opposed to other blood components. In 2012, the Balearic Islands Blood Bank (BIBB) implemented riboflavin and UV light PRT for plasma (Mirasol PRT, Terumo BCT Europe N.V.). 18 In 2013, the BIBB initiated universal routine use of riboflavin and UV light-treated PLTs for transfusion support in patients with thrombocytopenia. In this blood center, we have recently experimentally studied the effectiveness of riboflavin and UV light in eliminating T. cruzi from WB units. 19 The BIBB is one of the few blood banks worldwide with years of experience in the routine use of Mirasol PRT for plasma and PLTs, the two blood components for which this PRT is already commercialized, as well as experience in the experimental use of Mirasol PRT for WB. A retrospective study was conducted to investigate the efficacy, safety, and cost of riboflavin and UV light-treated PLT transfusions to patients with thrombocytopenia during 
MATERIALS AND METHODS
Study design
The BIBB collects and provides all blood components for 22 public and private hospitals in the Balearic Islands, which provide a total of 3675 beds for a population of approximately one million inhabitants. The BIBB obtains approximately 40,000 WB and 5700 PLT component donations per year (60% plateletpheresis and 40% WB-derived buffy coat PLTs) for transfusion therapy in different patient categories, such as hematology, oncology, medical, and surgery, including patients requiring cardiovascular surgery. There are two bone marrow transplant units and four cardiovascular surgery units in the archipelago.
The Balearic Islands University Hospital is the largest hospital in the region, comprehensively equipped with surgical and medical specialties. It has the largest hematology and oncology service in the archipelago, including the main bone marrow transplant unit. Around 60% of PLT transfusions in the Balearic Islands are carried out in this hospital. For all these reasons, the Balearic Islands University Hospital was selected for a retrospective analysis on the efficacy, safety, and cost of riboflavin and UV light-treated PLT transfusions to patients with thrombocytopenia.
Indications for PLT transfusion were based on widely accepted European guidelines. Basically, a PLT count of 10 × 10 9 /L was used as a prophylactic transfusion trigger in patients who were not bleeding or having invasive procedures or surgery. 20 The same transfusion PLT threshold was used in both periods. Information on PLT transfusions was analyzed for all patients receiving PLTs during the comparison and PRT periods at the Balearic Islands University Hospital, in accordance with the hospital ethics committee. The use of PLTs per patient was determined based on the number of patients who received PLTs and the total number of PLTs transfused. Patients were classified according to the primary diagnosis by the clinical service providing medical care and ordering blood components. Data on PLT transfusion reactions were obtained from the Balearic Island Hemovigilance System (BIHVS), while maintaining patient confidentiality.
In accordance with the European Directive 2005/61/EC on Hemovigilance, 21 in Spain, as in other European Community member countries, it is mandatory to report serious transfusion events occurring in medical centers to the health care authorities. The BIHVS is fully integrated into the Spanish Hemovigilance System. In addition to reporting serious transfusion events, mild and nonsevere transfusion reactions are also notified to the BIHVS.
Collection and preparation of PLT components Comparison period
During the 3-year comparison period, from January 2005 to December 2007, 60% of plateletpheresis components were collected using three automatic cellular separators (Trima, Terumo BCT Europe N.V.; Amicus, Fresenius Kabi; and Haemonetics MCS+, Haemonetics Corp.), and 40% of the PLT components were prepared from pools of five WBderived buffy coats using an automatic blood component processing system (COMPOMAT G4, Fresenius Kabi) and an automatic system (ORBISAC, Terumo BCT Europe N.V.). For components prepared from buffy coats, PAS (T-Sol, Fenwal, Inc.) was used in a ratio of approximately 35% plasma and 65% PAS. PLT concentrates obtained by apheresis were suspended in 100% plasma. For both methods, components were prepared like conventional PLT components in compliance with national regulatory requirements, that is, 75% of PLT units should have a PLT yield of at least 3 × 10 11 /U (Table 1) . 22 Gamma irradiation was applied to PLT components as required by specific patient indications. During the 3-year comparison period, the PLT storage time was 5 days.
Riboflavin and UV light PRT period
During the 3-year PRT period, from January 2013 to December 2015, all PLT components, WB-derived buffy coat PLTs as well as plateletpheresis, were prepared with T-PAS+ (Terumo BCT Europe N.V.) in a ratio of 35% plasma and 65% PAS. Pooled buffy coat PLT components, which represented 40% of the PLT production, were prepared using the automatic blood component processing system (COMPOMAT G4, Fresenius Kabi) and an automatic system (TACSI, Terumo BCT Europe N.V.). Likewise, 60% of apheresis PLTs was collected using three automatic cellular separators (Trima, Terumo BCT Europe N.V.; Amicus, Fresenius Kabi; and Haemonetics MCS+, Haemonetics Corp.). All PLT components-plateletpheresis and WB-derived buffy coat
PLTs-were treated with Mirasol PRT (Terumo BCT Europe N.V.), under CE Mark registration. Within the first 22 hours after collection, all PLT components were transferred into an illumination and storage bag and riboflavin solution was added (35 ± 5 mL). The PLT unit was placed in the illuminator and exposed to UV light for approximately 5 minutes with light energy in the range of 265 to 370 nm, according to the manufacturer's instructions.
In accordance with the national requirements, 75% of PLT units should have a PLT yield of at least 3 × 10 11 /U. 22 Therefore, the PLT target dose was increased to 3.5 × 10 11 /U during the PRT period to compensate for the expected 5% PLT loss due to the transfer step in the riboflavin and UV light PRT procedure. 23 PRT was used instead of gamma irradiation to meet specific patient indication requirements. PRT-treated PLTs were stored for up to 7 days. All PLTs in both periods were leukoreduced in accordance with European and national requirements (residual WBC content below 10 6 per unit in >90% of production). 22, 24 The proportion of plateletpheresis and production pools remained the same, that is, 60 and 40% for both periods ( Table 1) . The riboflavin and UV light PRT for PLT workflow was designed as follows ( Fig. 1) . First, the plateletpheresis units were inactivated, after a 2-hour resting period and before 22 hours postcollection, early in the morning on postcollection Day 1, while the infectious disease and immunohematology testing was performed in the laboratory. After the testing was performed, at 2 PM on Day 1 postcollection, the inactivated plateletpheresis units were ready for distribution. Second, after testing, the WBderived buffy coat PLTs were prepared late in the morning on Day 1, and inactivated before 8 hours of the WBderived buffy coat PLT preparation period and before 22 hours postcollection, according to the manufacturer's instructions. Since the PRT procedure lasts between 10 and 15 minutes, the inactivated WB-derived buffy coat PLTs were ready for release at approximately 5 to 6 PM at Day 1 postcollection.
Statistical analysis
BIBB data were collected from the computerized database used to manage the blood component inventory. While maintaining patient confidentiality, data on transfusion reactions related to PLTs were obtained from the BIHVS. Data for the Balearic Islands University Hospital were extracted from the hospital's computerized database, according to the hospital ethics committee. Values for all continuous variables were summarized as mean and standard deviations (SDs). Differences in mean values between the two observation periods were compared by a twosample t test. All p values reported were two-sided, and significance was determined at a p value of less than 0.05. Overall, there was a significant increase in the total number of PLT concentrates transfused at the Balearic Islands University Hospital during the PRT period, despite a lower number of patients receiving PLTs ( Table 2 ). The division of patients according to primary diagnosis was quite similar in both periods, except for the number of patients belonging to the cardiovascular category. This patient group experienced a marked decline, because additional cardiovascular services were opened in the Balearic Islands during the PRT period, and large numbers of patients were referred there instead of being attended at the Balearic Islands University Hospital. There was therefore a corresponding decrease in the number of PLT transfusions received by cardiovascular patients (Table 3) .
PLT utilization
The mean transfusion dose of PLTs per unit was similar for both periods. However, overall a higher number of PLT concentrates were transfused to fewer patients during the PRT period. Therefore, the mean number of PLT concentrates and the total dose of PLTs received by each patient were higher in the PRT period (Table 4) . Nevertheless, when analyzing PLT use per patient according to the primary diagnosis data, we observed that it was higher for hematology and medical and surgical categories (excluding cardiovascular surgery) in the PRT period. In contrast, in oncology and cardiovascular categories, the mean number of PLT concentrates and the total dose of PLTs received by the patients were similar for both periods (Table 5) .
Acute transfusion reactions
The frequency of febrile and allergic reactions in patients receiving PLT transfusions in the Balearic Islands University Hospital was significantly lower in the PRT period, despite the higher number of PLT concentrates transfused during that period (pre-PRT 6424 vs. post-PRT 9673; p = 0.004) and also despite the increase in the overall transfusion reaction notification rate to the BIHVS in the PRT-treated PLT period (pre-PRT 3.7 per 10,000 vs. post-PRT 9.9 per 10,000 transfusions; Table 6 ). There were no cases of PLT transfusion-related sepsis or transfusion-transmitted infections by agents such as L. infantum and T. cruzi and no other severe transfusion reactions in either period.
Economic impact of extended storage time due to riboflavin and UV light PRT
During the 3-year riboflavin and UV light PRT period, PRT implementation was associated with a 95.5% increase in PLT production costs compared to the control period. This increase in cost had two origins: 1) a gradual increment (+32.9%) in the demand for PLTs and 2) the expense of the riboflavin and UV light procedure itself (inactivation kits, sterile connections, dilution of PLT units in PAS, etc.), which represented a 46.9% cost increase (Table 7) .
Before the adoption of riboflavin and UV light PRT, when the expiry date for PLTs was set at 5 days, 16.8% of the PLTs produced by the BIBB became outdated. After the implementation of riboflavin and UV light PRT in routine practice, the PLT shelf life increased to 7 days, and the percentage of outdated PLTs declined substantially to 0.72%, a marked reduction of more than 95%. This decrease represented a 16.12% reduction in cost, taking into account the initial cost increase, or an overall saving of €284,805.58 over the 3-year PRT period (Table 7) .
It is also important to note that PRT implementation did not result in additional personnel working hours, neither in the daily routine nor during holiday periods, when maintaining an adequate PLT supply is generally more challenging. The riboflavin and UV light PRT procedure for PLTs is very simple and fast, taking only 10 to 15 minutes, and the treated PLTs are ready for release on Day 1 postcollection.
Additional cost savings associated with PRT, such as the elimination of cytomegalovirus (CMV) tests, gamma irradiation, and bacterial contamination screening, were not included in this study as they did not represent any significant cost to the BIBB. Since the implementation of universal leukoreduction in 2000, CMV testing is no longer carried out in the blood center. Gamma irradiation is performed in the department of radiotherapy at the Balearic Islands University Hospital upon demand for irradiated blood components and bacterial contamination screening is only used as a quality control test in a few units at the end of the storage time.
DISCUSSION
Despite progress in donor screening and laboratory testing, a small risk of bacterial, 25, 26 viral, 27, 28 or protozoal [12] [13] [14] [15] [16] contamination of PLTs persists. There is also a continuous risk from newly emerging blood transfusion-transmitted infectious agents. 8, 29, 30 The application of PRT for blood and blood components has the potential to reduce these risks. There are different PRT methods for plasma, PLTs, RBCs, and WB, either commercially available or under active development. The system discussed here is the Mirasol PRT, which uses riboflavin (vitamin B2) in combination with UV light and is commercially available for PLT concentrates and plasma in a number of countries. Briefly, the Mirasol PRT is a treatment based on the ease with which riboflavin can cross pathogen membranes and intercalate with their nucleic acids. Upon illumination with UV light, the riboflavin is activated, resulting in the destruction of the pathogen nucleic acid and preventing pathogen replication in blood components. 1 Presented here is our experience in routinely transfusing riboflavin and UV light-treated PLTs to patients with thrombocytopenia in a 3-year period. This system was compared in terms of efficacy, safety, and cost with the transfusion of nontreated PLTs to a comparison group of patients also during 3 years.
Our study shows that although the mean transfusional dose of PLTs per unit was similar for both periods, a higher number of PLT concentrates were transfused to fewer patients during the PRT period. When analyzing the PLT use per patient according to the primary diagnosis, we observed that the patients receiving most PLT transfusions were in the hematology and medical and surgical categories in the PRT period. In contrast, the number of PLT transfusions given to oncology and cardiovascular surgery patients was similar in both periods.
It has been described that PRT-treated PLTs seemingly present a hyperactivated state, which may explain their faster clearance and lower recirculation rates. 31 In fact, riboflavin and UV light treatment leads to hyperreactive PLTs, probably caused by continuous basal degranulation over storage time. 32 Whether or not this is a negative event is still under discussion, as activated PLTs are probably more efficient if a patient is suffering vascular damage. 33 On the other hand, from a practical point of view, it is important to bear in mind that most PLT transfusions are given prophylactically. So even though the transfusional dose is similar for untreated and PRT-treated PLTs, as in our study, if the PRT-treated PLTs remain in the bloodstream for less time, patients receiving them will be transfused more frequently due to lower posttransfusion PLT increments. Our results are in accordance with a randomized control trial (RCT) recently published by Rebulla and coworkers. 34 In this study, two noninferiority RCTs were conducted in parallel to compare the safety and efficacy of PLTs treated with two PRT systems, including riboflavin and UV light, with conventional PLTs. Unfortunately, the study was finalized before the planned sample size could be attained and without reaching any noninferiority conclusions. However, although the transfusional dose was similar for PRT-treated and nontreated PLTs, posttransfusion PLT count increments were significantly lower in patients receiving PRT-treated PLTs versus those receiving nontreated PLTs. Consequently, the mean PLT and RBC use was higher in PRT than control patients. Nevertheless, the authors conclude that PRT-treated PLTs show a high safety and efficacy 35 consisted of a noninferiority RCT to assess the efficacy and safety of riboflavin and UV light treatment for PLTs. Again, the noninferiority of riboflavin and UV light-treated PLTs could not be established, since the mean corrected count increment (CCI) values for both 1 and 24 hours were lower for the treated than nontreated PLTs. 35, 36 However, the authors found that the overall PLT and RBC usage in both groups was not significantly different, suggesting that the lower CCIs for riboflavin and UV light-treated PLTs did not increase blood product utilization. 35 It is also necessary to note that in vitro test results, like tests for PLT activation, are often unable to predict PLT function after transfusion, because a certain degree of functional recovery may occur. 37 There is a lack of correlation between in vitro results and clinical efficacy. 38, 39 Interestingly, as shown by the clinical trials available to date, even when riboflavin and UV light-treated PLTs are associated with a lower CCI or posttransfusion PLT count, this is not linked with an increased risk of bleeding. 34, 35 The same finding has been recently highlighted by a systematic review of PRT-treated PLTs for the prevention of bleeding in patients with hematologic or oncologic disorders. In fact, the authors state that although PRT-treated PLTs lead to an increased requirement for PLT transfusion, there is no evidence that they affect the risk of death, bleeding, or a serious side effect. The authors also point out that there is still insufficient evidence for patients with other diagnoses. 40 Currently in progress, the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial, a randomized, single-blinded, multicenter controlled trial, is aiming to evaluate the clinical noninferiority of riboflavin and UV light-treated PLTs compared with conventional PLTs, using the percentage of patients with WHO Grade 2 or more bleeding complications as the primary outcome. 41 It will be very interesting to see the results of this promising study, as it is likely to shed light on the true safety and efficacy profile of riboflavin and UV lighttreated PLTs. Additionally, our study showed that the frequency of febrile and allergic reactions in patients receiving PLT transfusions was lower in the PRT period despite the higher number of PLT concentrates transfused and the increase in the overall transfusion reaction notification rate to the BIHVS. Recent hemovigilance studies have also reported that the use of riboflavin and UV light-treated PLTs has the potential to reduce the frequency of transfusion reactions, specifically febrile and allergic reactions. 5, 6 It is known that PLTs suspended in an additive solution are associated with less allergic and febrile transfusion reactions than PLTs stored in 100% plasma. 42 Such reactions can also be prevented by the use of riboflavin and UV light to inactivate WBCs not removed by leukoreduction and thus avoid cytokine release by WBCs. Both plasma content and cytokine release in stored PLT concentrates have been involved in PLT transfusion reactions. 43, 44 The decrease of febrile and allergic reactions in patients receiving PRT-treated PLTs in our study could be related not only to the implementation of riboflavin and UV treatment but also because 100% of PLTs supplied during the PRT period were stored suspended in PAS. Additionally, there were no cases of PLT transfusion-related sepsis, transfusion-transmitted infections by agents such as L. infantum and T. cruzi, or any other severe adverse reaction in either period. All transfusion reactions observed after the initiation of transfusion of PRT-treated PLTs were mild. Decreasing the frequency and severity of transfusion reactions not only improves patient safety but also can reduce transfusion reaction management cost. 45 PRT cost is central to our third finding. Undoubtedly, PRT implementation is associated with a considerable increase in the cost of PLT production. As our research group has previously described, this cost increment can be offset by the savings associated with a lower percentage of outdated PLT units due to the extension of PLT shelf life from 5 to 7 days. 7 In the 3-year PRT period, the BIBB saved €284,805.58, which represents a 16.12% reduction in cost, taking into account the initial increase. This saving was due to the reduction of outdated PLTs from 16.8% to 0.72% after PRT implementation. This reduction in cost is far from negligible and is a factor to be considered when planning PRT implementation. In the United States, out of the millions of PLTs transfused annually, 25% of the WB-derived PLTs and 12.8% of apheresis PLT concentrates become outdated and have to be discarded. 46 As well as reducing the cost associated with a high percentage of PLT outdates, PRT can also circumvent the logistic and safety shortcomings of bacterial screening tests, including false-negative results responsible for the residual risk of bacterial contamination in PLT transfusions. 25, 26 In conclusion, from the PLT production viewpoint, riboflavin and UV light PRT for PLTs is an easy and fast procedure that only takes 10 to 15 minutes. Moreover, it improves PLT transfusion safety by reducing the occurrence of febrile and allergic reactions and avoiding severe transfusion reactions. From the viewpoint of patient care, it seems that the number of PLT transfusions needed in some patient categories is higher after riboflavin and UV light treatment. PRT implementation certainly involves an increase in PLT production cost, but this can be partially offset by significant savings due to an increase in PLT shelf life from 5 to 7 days. This cost reduction could be a key factor in PRT implementation decision making, especially in settings where inventory management is challenged by a high percentage of wasted PLTs because of outdating. 46 
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